Alpha Cognition Grants Stock Options to New Employee as Hiring Incentive

Alpha Cognition granted stock options to purchase 6,000 shares to a newly hired non-executive employee at an exercise price of $8.70 per share, reflecting the grant-date closing price. The options vest over three years with one-third vesting after the first year and the remaining two-thirds vesting in equal quarterly installments, contingent on continued employment. The award was issued under the company's 2026 Inducement Grant Plan, designed for attracting new talent to the biopharmaceutical firm.

Alpha Cognition, a biopharmaceutical firm focused on treatments for neurodegenerative conditions like Alzheimer's disease, used its 2026 Inducement Grant Plan to attract a new non-executive team member. The grant consisted of options on 6,000 shares with a strike price matching the stock's closing value on the grant date. This vesting structure—one-third after year one, then quarterly installments over two additional years—ties employee retention directly to equity participation, a common practice in competitive life sciences hiring.

The company's existing pipeline includes ZUNVEYL, an approved Alzheimer's treatment, and ALPHA-1062 in development for moderate-to-severe dementia and traumatic brain injury-related cognitive impairment. Using equity awards as hiring incentives allows early-stage and commercial-stage biotech firms to conserve cash while offering meaningful long-term compensation tied to company performance and employee longevity.